Phase 1 Trial Finds Potential Parkinson’s Vaccine, Affitope PD01A, to be Safe and Possibly Effective
(May 29, 2018) – Affiris’ experimental Parkinson’s vaccine, Affitope PD01A, is safe and effectively triggers an immune response against the alpha-synuclein (aSyn) protein, data from a series of four consecutive clinical trials show. Read more…